223 related articles for article (PubMed ID: 35630016)
1. Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward.
Rizzo A; Cusmai A; Gadaleta-Caldarola G; Palmiotti G
Medicina (Kaunas); 2022 Apr; 58(5):. PubMed ID: 35630016
[TBL] [Abstract][Full Text] [Related]
2. KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer.
Rizzo A; Cusmai A; Acquafredda S; Giovannelli F; Rinaldi L; Misino A; Palmiotti G
Future Oncol; 2022 Jun; 18(18):2301-2309. PubMed ID: 35378995
[TBL] [Abstract][Full Text] [Related]
3. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis.
Latif F; Bint Abdul Jabbar H; Malik H; Sadaf H; Sarfraz A; Sarfraz Z; Cherrez-Ojeda I
Expert Rev Anticancer Ther; 2022 Feb; 22(2):229-235. PubMed ID: 34949142
[TBL] [Abstract][Full Text] [Related]
4. Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis.
Rizzo A; Cusmai A; Massafra R; Bove S; Comes MC; Fanizzi A; Rinaldi L; Acquafredda S; Gadaleta-Caldarola G; Oreste D; Zito A; Giotta F; Lorusso V; Palmiotti G
Cells; 2022 Jun; 11(12):. PubMed ID: 35740985
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemoimmunotherapy in early triple-negative breast cancer: a new kid on the block?
Rizzo A; Palmiotti G
Immunotherapy; 2022 Jul; 14(10):755-758. PubMed ID: 35642433
[No Abstract] [Full Text] [Related]
6. Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better?
Song F; Tarantino P; Garrido-Castro A; Lynce F; Tolaney SM; Schlam I
Curr Oncol Rep; 2024 Jan; 26(1):21-33. PubMed ID: 38198112
[TBL] [Abstract][Full Text] [Related]
7. Current usage of pembrolizumab in triple negative breast cancer (TNBC).
O'Rourke H; Hart C; De Boer RH
Expert Rev Anticancer Ther; 2024 May; 24(5):253-261. PubMed ID: 38594892
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Mittendorf EA; Zhang H; Barrios CH; Saji S; Jung KH; Hegg R; Koehler A; Sohn J; Iwata H; Telli ML; Ferrario C; Punie K; Penault-Llorca F; Patel S; Duc AN; Liste-Hermoso M; Maiya V; Molinero L; Chui SY; Harbeck N
Lancet; 2020 Oct; 396(10257):1090-1100. PubMed ID: 32966830
[TBL] [Abstract][Full Text] [Related]
9. Progress in immune checkpoint inhibition in early-stage triple-negative breast cancer.
Mohamed A; Kruse M; Tran J
Expert Rev Anticancer Ther; 2023; 23(10):1071-1084. PubMed ID: 37747062
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in Triple-Negative Breast Cancer.
Emens LA
Cancer J; 2021 Jan-Feb 01; 27(1):59-66. PubMed ID: 33475294
[TBL] [Abstract][Full Text] [Related]
11. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
Schmid P; Cortes J; Dent R; Pusztai L; McArthur H; Kümmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Untch M; Fasching PA; Cardoso F; Andersen J; Patt D; Danso M; Ferreira M; Mouret-Reynier MA; Im SA; Ahn JH; Gion M; Baron-Hay S; Boileau JF; Ding Y; Tryfonidis K; Aktan G; Karantza V; O'Shaughnessy J;
N Engl J Med; 2022 Feb; 386(6):556-567. PubMed ID: 35139274
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials.
Tarantino P; Gandini S; Trapani D; Criscitiello C; Curigliano G
Crit Rev Oncol Hematol; 2021 Mar; 159():103223. PubMed ID: 33482345
[TBL] [Abstract][Full Text] [Related]
14. Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?
Bonadio RC; Tarantino P; Testa L; Punie K; Pernas S; Barrios C; Curigliano G; Tolaney SM; Barroso-Sousa R
Cancer Treat Rev; 2022 Nov; 110():102459. PubMed ID: 35998514
[TBL] [Abstract][Full Text] [Related]
15. Clinical trials of immunotherapy in triple-negative breast cancer.
Howard FM; Pearson AT; Nanda R
Breast Cancer Res Treat; 2022 Aug; 195(1):1-15. PubMed ID: 35834065
[TBL] [Abstract][Full Text] [Related]
16. Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: a systematic review and meta-analysis.
Rizzo A; Schipilliti FM; Di Costanzo F; Acquafredda S; Arpino G; Puglisi F; Del Mastro L; Montemurro F; De Laurentiis M; Giuliano M
ESMO Open; 2023 Dec; 8(6):102198. PubMed ID: 38100933
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?
Giugliano F; Valenza C; Tarantino P; Curigliano G
Expert Opin Investig Drugs; 2022 Aug; 31(8):855-874. PubMed ID: 35762248
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy and breast cancer: an overview.
Mezni E; Behi K; Gonçalves A
Curr Opin Oncol; 2022 Sep; 34(5):587-594. PubMed ID: 35838204
[TBL] [Abstract][Full Text] [Related]
19. How shall we treat locally advanced triple negative breast cancer?
Luz P; Dias D; Fortuna A; Bretes L; Gosalbez B
F1000Res; 2019; 8():1649. PubMed ID: 32802311
[TBL] [Abstract][Full Text] [Related]
20. Novel Neoadjuvant Treatment Strategies for Triple-Negative Breast Cancer.
Davis AA; Gradishar WJ
Oncology (Williston Park); 2020 May; 34(5):176-182. PubMed ID: 32644178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]